3SBioSTU:83B -3.65%90 Gross Margin % is 94.69% as of Dec. 2025, which is 15% above its 10-year median of 82.64. GuruFocus rates STU:83B with a GF Score™ of 90/100 and a GF Value™ of €1.52 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 734 Biotechnology companies, 3SBio ranks better than 88.42% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. 3SBio's Gross Profit for the
six
months ended in Dec. 2025 was €1,532 Mil. 3SBio's Revenue for the
six
months ended in Dec. 2025 was €1,618 Mil. Therefore, 3SBio's Gross Margin % for the quarter that ended in Dec. 2025 was 94.69%.
The historical rank and industry rank for 3SBio's Gross Margin % or its related term are showing as below:
STU:83B'
s Gross Margin % Range Over the Past 10 Years
Min: 80.86 Med: 82.64 Max: 92.4
Current: 92.4
During the past 12 years, the highestGross Margin % of 3SBio was 92.40%. The lowest was 80.86%. And the median was 82.64%.
STU:83B's Gross Margin % is ranked better than 88.42% of 734
companies
in the Biotechnology industry
Industry Median: 60.795
vs STU:83B: 92.40
3SBio had a gross margin of 94.69% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for 3SBio was 2.30% per year.
3SBio (STU:83B) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
3SBio had a gross margin of 94.69% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
3SBio Gross Margin % Related Terms
3SBio Gross Margin % Historical Data
* Premium members only.
The historical data trend for 3SBio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:83B vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, 3SBio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where 3SBio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
3SBio (STU:83B) has a Gross Margin % of 94.69% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on 3SBio and its competitors. This is 15% above median its historical median of 82.64. Over the past decade, 3SBio's Gross Margin % has ranged from 80.86 to 92.40. According to the industry distribution chart, 3SBio ranks #85 out of 734 companies in the Biotechnology industry, placing it in the top 11.6%.
Is 3SBio's Gross Margin % too high?
3SBio's current Gross Margin % of 94.69% is 15% above median its 10-year median of 82.64. Over the past 10 years, this metric has ranged from a low of 80.86 to a high of 92.40. The Biotechnology industry median Gross Margin % is 60.80. 3SBio's value of 94.69% is 55.8% above this industry median. Based on the distribution chart, 3SBio ranks #85 out of 734 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #85 out of 734 companies for Gross Margin %. This places 3SBio in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.80. 3SBio's value of 94.69% is 55.8% above this benchmark. Historically, 3SBio's own Gross Margin % has ranged from 80.86 to 92.40 over the past decade. While the company's 10-year median is 82.64 vs. the industry median of 60.80, 3SBio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current Gross Margin % of 94.69% is 55.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on 3SBio and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current Gross Margin % is 94.69%, which is 15% above median its own 10-year median of 82.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.52, compared to a current price of €1.84 — trading 20.7% above its estimated fair value. The current Gross Margin % is 94.69%, which is 15% above median its 10-year median of 82.64 and 55.8% above the Biotechnology industry median of 60.80. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For 3SBio (STU:83B), the current Gross Margin % is 94.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.84 is trading 20.7% above its estimated GF Value™ of €1.52.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
Gross Margin %: 94.69% (15% above median its 10-year median of 82.64)
GF Value™: €1.52 vs. price of €1.84 (20.7% above fair value)
Industry Position: 55.8% above the Biotechnology median (#85 of 734)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for STU:83B
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
